CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluat
Research type
Research Study
Full title
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
IRAS ID
151181
Contact name
Kevin Harrington
Contact email
Sponsor organisation
Bristol-Myers Squibb International Corporation
Eudract number
2013-003622-86
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
Research summary
Summary of Results
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) - Study Results - ClinicalTrials.gov
: https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fu2790089.ct.sendgrid.net%2Fls%2Fclick%3Fupn%3DXv3JSvJ-2B3M71ppf7N9agbRehJ-2Fi4xyo44sEgJVCl5Bdj8o1FpylFwbn362DUDJ-2FzxKJRLItfhz1ysXQ9g01tNnyVeH-2Fbi3VmqeCDhmotIM7KDVOO-2FYuirhLW9DMJmsNAHRcZ0wqyLEn3P-2B9ZrJmlnQ-3D-3DK2Ve_E1aO2-2BZlVOSJJV-2FajQqskegTd6IRomHYTi-2Fbt8SH3YKo-2BKxHcGvO2Hh-2B-2FjSr8dwlh9jy9lHWTcTsNaVxWwQNgUp6ElhNGGWPYn5chkR9WMeh7DrghSJNajdIymBB21XHfXlT-2FKyMAEJnWGby8Q3ki7to51xjG0iuNAgzFCg0VFKc6lhRZZtqjNsM9KeyajnQazIw9kcvXT0vNvDQFIPr2w-3D-3D&data=05%7C01%7Capprovals%40hra.nhs.uk%7C4ab3523bd42b44e8eeec08da81cec0b7%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C637965022242746921%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=coycS%2F56%2Bd%2BLPJkAdrqnV4Jw%2FPOEyayD6E3nVVo8fiY%3D&reserved=0
REC name
South Central - Berkshire Research Ethics Committee
REC reference
14/SC/0199
Date of REC Opinion
8 May 2014
REC opinion
Further Information Favourable Opinion